ABCD is pleased to announce the launch of the ABCD nationwide empagliflozin audit and would like to invite all ABCD members to take part.
With the launch of this audit we now have parallel audits of all three SGLT2 inhibitors allowing us in future to look at the class as a whole and to compare and contrast among the different classes. The online tool for the audit has a very easy to use sophisticated data analysis tool making it quick and easy to analyse your own local audit data. An ideal project for SpR, DSN or medical student if you do not have time yourself.
To register for the audit click HERE
To find out more click HERE
ALL CONTRIBUTORS TO THE AUDIT WILL BE LISTED ON PUBLICATIONS AND PRESENTATIONS ETC - EXACTLY AS OCCURRED IN OUR PREVIOUS AUDITS.
We look forward to welcoming you on board with this latest venture
